Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of ...

The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their ...

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

| Avoid common pitfalls in EU orphan drug market access—learn how local expertise can help navigate pricing, reimbursement, ...

As the demand for high-quality, GMP-compliance software continues to grow across global markets, this new Spanish-language website enables more manufacturers to streamline operations, enhance ...

After a momentous 2024, Culver City-based ImmunityBio Inc., the immunotherapy company founded and majority-owned by ...

The broad definition of counterfeit is a fake or unauthorised copy of a genuine product, typically medicines, designer ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ: CYTK) stands ...

If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your ...